Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis.

ABSTRACT:

Background

Pimavanserin, a selective 5-HT_2A inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis.

Aim

We aimed to evaluate motor- and cognition-related safety in pimavanserin-treated patients with PD psychosis.

Methods

This analysis included patients with PD psychosis treated with pimavanserin 34 mg from a pooled analysis of 3 randomized, double-blind, placebo-controlled, 6-week studies [NCT00477672 (study ACP-103-012), NCT00658567 (study ACP-103-014), and NCT01174004 (study ACP-103-020)] and a subgroup of patients with PD dementia with psychosis from HARMONY (NCT03325556), a randomized discontinuation study that included a 12-wee

SUBMITTER: Abler V 

PROVIDER: S-EPMC9580496 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature